Dizal will also present results from the ongoing Phase I/II study of DZD6008, a 4th generation EGFR TKI with full BBB penetration, in advanced EGFR mutation positive (EGFRm) non-small cell lung cancer ...

Roivant Sciences secures $5.2B for advancing late-stage drugs like IMVT-1402 & brepocitinib. Click here to read an analysis ...

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 150+ ...

Newer-generation Bruton's tyrosine kinase (BTK) inhibitors have found a place in the management of follicular lymphoma, a ...

HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED including savolitinib, ...

Merck , known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2025. "Our company made strong progress to start the year, with increasing ...